Strengthening healthcare through strategic collaboration with government institutions.
Al-Qawsan Scientific Bureau maintains a long-standing and strategic relationship with Iraq's Ministry of Health, the national authority responsible for pharmaceutical regulation, public health policy, and the oversight of all healthcare activities across the country.
Our collaboration with the Ministry encompasses several critical areas. We work closely with the regulatory division on the registration and accreditation of pharmaceutical factories and products, ensuring that all medications entering the Iraqi market meet the required safety and efficacy standards. This includes the preparation and submission of technical dossiers, facility inspection coordination, and ongoing compliance monitoring.
Beyond regulatory affairs, Al-Qawsan has played a central role in national health initiatives — most notably as the exclusive distributor of the Sinopharm COVID-19 vaccine during the pandemic, supporting the Ministry's nationwide vaccination campaign across all 18 governorates.
We also contribute to healthcare professional training programmes organised in partnership with the Ministry, providing workshops and seminars on the latest treatment protocols, pharmacological advances, and product knowledge.
National healthcare authority
Baghdad, Iraq
Full lifecycle management of pharmaceutical factory accreditation and individual product dossier submission to the Ministry of Health.
Continuous monitoring of Iraqi pharmaceutical regulations and preparation of technical dossiers aligned with local and international standards.
Cold-chain logistics, site coordination and safe, timely delivery of doses across all 18 governorates during national immunization campaigns.
Specialised workshops, seminars and continuing-education programmes for healthcare professionals on latest treatment protocols and products.
Kimadia (The State Company for Marketing Drugs and Medical Appliances) is the Iraqi government entity responsible for the centralised procurement, importation, and distribution of pharmaceutical products and medical supplies to all public healthcare facilities nationwide.
Operating under the Iraqi Ministry of Health, Kimadia manages large-scale public tenders for the supply of essential medicines, medical devices, laboratory equipment, and hospital supplies to government hospitals, health centres, and clinics across all Iraqi governorates.
Al-Qawsan participates actively in Kimadia's procurement processes, submitting competitive bids for pharmaceutical supply contracts and providing high-quality, competitively priced medications from our network of international manufacturers. Our deep understanding of Kimadia's bidding requirements, documentation standards, and delivery protocols positions us as a reliable partner in serving Iraq's public health sector.
Through this collaboration, we contribute directly to ensuring that essential medicines remain accessible and affordable in Iraq's public healthcare system, supporting the government's mission of universal health coverage.
Preparation and submission of competitive bids for pharmaceutical supply contracts, with full documentation and regulatory compliance.
Identification of high-demand therapeutic categories and strategic sourcing from our international network of manufacturers.
Best-value offers structured for public tenders, balancing affordability with quality standards required by Iraqi healthcare institutions.
GMP-compliant warehousing, customs clearance and last-mile delivery to public hospitals, health centres and clinics across all governorates.
The State Company for Drug Industries (SDI), headquartered in Samarra, is Iraq's pioneering public pharmaceutical manufacturer. Established in 1965, SDI was the first pharmaceutical manufacturing facility in Iraq and remains a cornerstone of the country's domestic drug production capacity.
SDI operates under the Iraqi Ministry of Industry and Minerals and produces a broad range of essential generic medicines, medical supplies, and healthcare products for distribution through public sector channels. The company's facilities include production lines for tablets, capsules, syrups, injectable solutions, and ointments.
Al-Qawsan's collaboration with SDI focuses on bridging the gap between public manufacturing and market distribution, ensuring that locally produced pharmaceuticals reach pharmacies, hospitals, and clinics efficiently across all governorates. This partnership supports Iraq's strategic objective of reducing dependence on pharmaceutical imports and strengthening domestic production capabilities.
State Company for Drug Industries
Ministry of Industry & Minerals
Samarra, Iraq
Trusted distribution partner bridging SDI's public manufacturing with pharmacies, clinics and private healthcare networks nationwide.
Tablets, capsules, syrups, injectables and ointments produced locally — a full essential-medicine range covering major therapeutic categories.
Leveraging Al-Qawsan's 20+ distribution hubs to ensure SDI products reach every governorate — from urban centres to remote areas.
Long-term partnership supporting Iraq's strategic objective of strengthening domestic pharmaceutical production and reducing import dependence.
During the global COVID-19 crisis, Al-Qawsan stood at the forefront of Iraq's response. As the exclusive distributor of Sinopharm's vaccine, we facilitated the safe and timely delivery of doses across the country in coordination with the Ministry of Health.
Active and consistent participation in Kimadia's national pharmaceutical tenders, supplying essential medicines and medical devices to government hospitals and public health facilities across all Iraqi governorates.
Comprehensive management of pharmaceutical factory and product registration with the Ministry of Health, including technical dossier preparation, inspection coordination, and ongoing compliance management.
Organisation of specialised workshops and seminars for healthcare professionals in partnership with the Ministry of Health, covering treatment protocols, pharmacological advances, and continuing medical education.
